By linking health data from two rheumatology services in Wales to hospital and primary care records, we assess the role of non-anti-IL-6 bDMARDs and anti-IL-6 bDMARDs (tocilizumab and sarilumab) in the management of RA in a real-world setting. Here, IL6 is linked to rheumatoid arthritis.